San Francisco Bay Area biotech stories.
Tuesday, July 31, 2012
Drug developer CytomX expands Series B by $11 million, looks to make key hires
CytomX Therapeutics Inc.
expanded its $41 million Series B financing round by
adding $11 million
from venture capital firm
. The South San Francisco company,
which in September 2010 raised $30 million
from Third Rock Ventures and Roche Venture Fund, is developing highly targeted antibodies, which it calls Probodies. Those potential cancer and inflammatory disease treatments unmask their antibody-drug payloads only when they enter the "microenvironment" of diseases.
Share to Twitter
Share to Facebook
Share to Pinterest
Roche Venture Fund
Post a Comment
Post Comments (Atom)